Changing epidemiology, global trends and implications for outcomes of NAFLD

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common liver disease globally and is currently estimated to affect 38% of the global population. Only a minority of patients with NAFLD will progress to cirrhosis or hepatocellular carcinoma, but from this vast population the total number of patients who are at risk of such severe outcomes is increasing. Worryingly, individuals are increasingly being affected by NAFLD at an earlier age, meaning there is more time for them to develop severe complications. With considerable changes in dietary composition and urbanisation, alongside the growth in obesity and type 2 diabetes in the global population, in particular in developing countries, the…

• BS
  Bristol-Myers Squibb
• P
  Pfizer
• GS
  Gilead Sciences
• GP
  GW Pharmaceuticals
• KC
  Kowa Company
• V
  Vetenskapsrådet

  Award: 2021-01293
• CU
  Chinese University of Hong Kong

  Award: 2021.027